UNSPSC 51162636: Guaiacolsulfonate or sulfoguaiacolum

This classification denotes an antitussive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 713AJ00NPG. European Medicines Agency schedules Sulfogaiacol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10740MIG.

Sulfogaiacol generally arises in the molecular formula C7H8O5S.K. The term SULFOGAIACOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, no. 3 1962, list 4.) SULFOGAIACOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: C1=CC=C(C(=C1)OCO)S(=O)(=O)[O-].[K+].

UNSPSC 51162636 Guaiacolsulfonate or sulfoguaiacolum is a Commodity code nominally identifying a specific pharmaceutical compound, but recent state and local solicitations tagged to this code do not reflect procurement of that chemical. Instead, the tagged opportunities target parenteral pharmaceutical products and services — intravenous solutions, total parenteral nutrition preparations, naloxone, and drug deactivation systems — procured by correctional and public health authorities to support medically necessary care and community health initiatives. The issuing bodies include state departments of corrections and county health agencies; these solicitations emphasize service delivery capability, same-day turnaround requirements, and compliance with state licensing and insurance standards rather than commodity sourcing alone.

The Washington State Department of Corrections posted RFQ RFQQK13020 on September 8, 2026, seeking parenteral products and services for eight correctional facilities across the state, with a response deadline of October 7, 2026 and a pre-bid conference on September 23, 2026; the solicitation encourages qualified small business, minority-owned, women-owned, and veteran-owned enterprise participation under state set-aside targets and requires delivery of parenteral nutrition bags within 24 hours of order and other parenteral products within 8 hours. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The code shows activity concentrated in the Pacific Northwest and Southeast, though the mismatch between the code's nominal chemical scope and the actual work being procured suggests the opportunities may be misclassified within state and local systems.